BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Valeant Gets $125M Up Front from GSK in Epilepsy Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Valeant Gets $125M Up Front from GSK in Epilepsy Deal
Aug. 29, 2008
By
Catherine Hollingsworth
No Comments
Valeant Pharmaceuticals International and GlaxoSmithKline plc said they are collaborating on the investigational drug retigabine for epilepsy, a deal that gives Valeant a $125 million up-front payment. (BioWorld Today)
BioWorld